Rainer Kramer has been appointed chief business officer at Immatics Biotechnologies GmbH in Germany to help the company commercialise its portfolio of therapeutic cancer vaccines. Dr Kramer was previously CBO at Signature Diagnostics, an oncology diagnostics company. Before that he was vice president for business development at Jerini AG which was bought by Shire Plc in 2008. Dr Kramer holds a diploma in molecular biology from the University of Regensburg and a PhD from the Max-Planck-Institute for Neurobiology.
Copyright 2012 Evernow Publishing Ltd